Currently, the information shows that CTRP3 inhibits the synthesis of glycogen and triglycerides in the liver, increases lipid oxidation in the liver, reduces fat synthesis in adipose tissue, and inhibits systemic inflammation, thereby participating in the regulation of blood sugar homeostasis, reducing insulin resistance and prevention the development of diabetes complications. The gene discussed is C1QTNF3; the disease is Insulin resistance.